Sign up to save your podcasts
Or
Share Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dived deep into the world of myeloproliferative neoplasms (MPNs), focusing specifically on polycythemia vera (PV) and essential thrombocythemia (ET). They are joined by Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, who shared his expertise on the latest treatment paradigms and risk stratification strategies for these conditions.
Key topics discussed included:
• The importance of ruling out secondary causes of erythrocytosis in PV patients.
• The role of JAK2 mutation testing and EPO levels in diagnosis of PV.
• Treatment options for PV, including phlebotomy, hydroxyurea, and interferon, as well as the emerging role of ruxolitinib.
• Risk stratification in ET and the significance of driver mutations like JAK2, CALR, and MPL.
• The management of acquired von Willebrand disease in patients with high platelet counts.
• Insights from Dr. Kuykendall's recent ASCO plenary presentation on the VERIFY Study and the potential of resveratide in PV treatment.
Join us for an informative discussion that highlights the evolving landscape of MPN management and the importance of individualized treatment plans.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to check out our other hematology episodes for more insights into challenging cases and treatment algorithms!
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dived deep into the world of myeloproliferative neoplasms (MPNs), focusing specifically on polycythemia vera (PV) and essential thrombocythemia (ET). They are joined by Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, who shared his expertise on the latest treatment paradigms and risk stratification strategies for these conditions.
Key topics discussed included:
• The importance of ruling out secondary causes of erythrocytosis in PV patients.
• The role of JAK2 mutation testing and EPO levels in diagnosis of PV.
• Treatment options for PV, including phlebotomy, hydroxyurea, and interferon, as well as the emerging role of ruxolitinib.
• Risk stratification in ET and the significance of driver mutations like JAK2, CALR, and MPL.
• The management of acquired von Willebrand disease in patients with high platelet counts.
• Insights from Dr. Kuykendall's recent ASCO plenary presentation on the VERIFY Study and the potential of resveratide in PV treatment.
Join us for an informative discussion that highlights the evolving landscape of MPN management and the importance of individualized treatment plans.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to check out our other hematology episodes for more insights into challenging cases and treatment algorithms!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
320 Listeners
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
116 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
290 Listeners
White Coat Investor Podcast
2,429 Listeners
The Curbsiders Internal Medicine Podcast
3,334 Listeners
Core IM | Internal Medicine Podcast
1,149 Listeners
The ONS Podcast
200 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Oncology Today with Dr Neil Love
56 Listeners
Two Onc Docs
185 Listeners